Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us
Conference Highlights
American Society of Hematology (ASH)
ASH 2018 – CLL
ASH 2018 – CLL
Ibrutinib 7-Year Follow-Up Data in First-Line and Relapsed/Refractory Patients with CLL/SLL
ASH 2018 – CLL
After 7 years of follow-up, sustained progression-free survival and overall survival rates were seen with ibrutinib, as well as stable or improved complete response rates over time.
Read More ›
Prognostic Testing and Treatment Approaches in Patients with CLL: Interim Analysis of the informCLL Real-World Registry
ASH 2018
,
ASH 2018 – CLL
informCLL registry analysis revealed that prognostic testing patterns in the real-world setting remain suboptimal despite inclusion in National Comprehensive Cancer Network and International Workshop on Chronic Lymphocytic Leukemia guidelines.
Read More ›
Cost-Effectiveness Comparison of Ibrutinib, Chemotherapy, and Chemoimmunotherapy in First-Line Treatment of CLL
ASH 2018 – CLL
Although ibrutinib is generally cost-effective in first-line use compared with chemotherapy and chemoimmunotherapy, a subset of ibrutinib-treated patients with cardiovascular events had a mitigating impact on the total cost of care.
Read More ›
ECOG-ACRIN Cancer Research Group: Phase 3 Study of Ibrutinib-Based Therapy in Untreated Younger Patients with CLL
ASH 2018 – CLL
In a phase 3 study, the combination of ibrutinib and rituximab provided superior progression-free survival and overall survival relative to the combination of fludarabine, cyclophosphamide, and rituximab for younger patients with previously untreated chronic lymphocytic leukemia (CLL)
Read More ›
Acalabrutinib in Patients with Relapsed/Refractory and High-Risk, Treatment-Naïve CLL
ASH 2018 – CLL
Researchers evaluating the Bruton’s tyrosine kinase inhibitor acalabrutinib monotherapy in relapsed/refractory and high-risk, treatment-naïve chronic lymphocytic leukemia (CLL) patients reported high response rates and an acceptable safety profile.
Read More ›
Frontline Ibrutinib Treatment Is Associated with Lower Total Cost of Care Compared with Chemoimmunotherapy in Patients with CLL
ASH 2018 – CLL
Using a national claims database, researchers found that previously untreated patients receiving chemoimmunotherapy had a higher total cost of care compared with patients receiving single-agent ibrutinib.
Read More ›
Ibrutinib Treatment in Waldenström’s Macroglobulinemia: Follow-Up Efficacy and Safety from the iNNOVATE Study
ASH 2018 – CLL
This phase 3 follow-up analysis evaluates the efficacy and safety of ibrutinib, alone and in combination with rituximab, in patients with Waldenström’s macroglobulinemia.
Read More ›
Dual Inhibition of Bruton’s Tyrosine Kinase and BCL2: A Promising Therapeutic Strategy for Myeloid and Lymphoid Leukemias
ASH 2018 – CLL
In an ex vivo analysis, the combination of venetoclax and ibrutinib showed encouraging biologic activity in several leukemia subtypes, including acute myeloid leukemia, acute lymphoblastic leukemia, and chronic lymphocytic leukemia.
Read More ›
Combined Ibrutinib and Venetoclax in Patients with Treatment-Naïve High-Risk CLL
ASH 2018 – CLL
In a phase 2 trial, the combination of ibrutinib and venetoclax was effective in patients with previously untreated, high-risk chronic lymphocytic leukemia (CLL), with no unforeseen safety signals.
Read More ›
MURANO Study: The Impact of Minimal Residual Disease on Long-Term Clinical Outcomes After Venetoclax plus Rituximab
ASH 2018
,
ASH 2018 – CLL
Researchers evaluated venetoclax plus rituximab versus bendamustine plus rituximab in inducing deep, durable responses in patients with chronic lymphocytic leukemia, as measured by the rate of minimal residual disease.
Read More ›
Page 1 of 2
1
2
Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us